What your doctor may not know about cholesterol
Confusion over cholesterol issues is everywhere and shared by most people, including doctors. Unfortunately, it means that, by seeing your primary care doctor or even cardiologist, you are being advised with information that is superficial and largely ineffective while ignoring the MANY issues that really should be addressed to manage risk for cardiovascular disease. Admittedly, these are somewhat complicated issues and even I have been guilty at times of giving overlysimplistic answers. I’ll try to keep this as straightforward as possible, but it is a bit hairy. I blame this situation on the statin drug industry, as they have painted a misleading picture that, if you take a statin drug or reduce LDL cholesterol, you are absolved of cardiovascular risk. The exaggerated statistical manipulations used by industry—“Lipitor reduces cardiovascular events by 36%” when the real value is, at best, 1%, not to mention the fact that the majority of statin data was paid for by statin manufacturers, a big no-no in any other industry—persuaded practitioners that statins and cholesterol reduction were virtual cures. They are not, of course, as anyone in healthcare who witnesses all the people admitted to the hospital with heart attacks, angina, and sudden cardiac death taking statin drugs will attest. The statin drug industry has therefore caused doctors to wear blinders, rarely looking beyond statins and cholesterol So what exactly don’t they know about ...
Conclusion: Use of RAS blockers (ACEI or ARB) in uncomplicated as well as complicated hypertensive patients with type 2 diabetes is sub-optimal. Most of the patients are on one drug and prescription of ≥3 drugs are rare. Statins are prescribed in only a half. PMID: 31321925 [PubMed - in process]
Publication date: August 2019Source: Nutrition, Metabolism and Cardiovascular Diseases, Volume 29, Issue 8Author(s): Marialaura Bonaccio, Augusto Di Castelnuovo, Simona Costanzo, Mariarosaria Persichillo, Amalia De Curtis, Chiara Cerletti, Maria Benedetta Donati, Giovanni De Gaetano, Licia Iacoviello
Publication date: Available online 19 July 2019Source: Pharmacological ResearchAuthor(s): Chiara Pavanello, Andrea Baragetti, Adriana Branchi, Liliana Grigore, Samuela Castelnuovo, Eleonora Giorgio, Alberico L. Catapano, Laura Calabresi, Monica GomaraschiAbstractLysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesteryl esters (CE) and triglycerides (TG) within the lysosomes; generated cholesterol and free fatty acids (FFA) are released in the cytosol where they can regulate their own synthesis and metabolism. When LAL is not active, as in case of genetic mutations, CE and TG accumulate in the lysosomal c...
Introduction: Statins are prescribed for patients with cardiovascular disease (CVD), along with the recommendation of adopting healthy diets. This stufy aimed to evaluate the independent and the combined effect of statins and Mediterranean diet (MD) towards mortality risk in subjects with previous CVD by using real-life data from a population-based prospective cohort. We performed a longitudinal analysis on 1,180 subjects (mean age 67.7 ± 10) with prior CVD at enrollment in the Moli-sani study and followed up for 7.9 years (median).
This study investigated the effects of statin in AF patients who experienced acute ischemic stroke.MethodsData from patients with AF experiencing first-ever ischemic stroke between 2001 and 2010 were collected from the Taiwan National Health Insurance Research Database and categorized into non-statin and statin groups. The statin group was further divided into pre-stroke statin (those who began statin therapy before stroke) and post-stroke statin (those who began statin therapy after stroke) groups. The risks for recurrent ischemic stroke, coronary artery disease (CAD), intracranial hemorrhage (ICH), and 1-year mortality w...
Hypertriglyceridemia (HTG) is associated with increased cardiovascular disease (CVD) risk. However, the cost burden of HTG-related CVD in high-risk US adults on statins has not been well characterized.
Conclusion The prevalence of statin induced new onset of diabetes is 7.03%. The main risk factors identified in the study were in older patients (≥60 years), rosuvastatin therapy, high dose and longer duration of statin therapy. PMID: 31311373 [PubMed - as supplied by publisher]
Here ’s the new list of what your health insurance plan might cover next year under Trump Treasury’s broadened definition of preventative care services.
Conclusion: Statin can be used as an adjuvant to erythropoietin in management of anemia in patients of chronic kidney disease, who show hyporesponsiveness to increased doses of erythropoietin, by its anti-inflammatory properties. PMID: 31313547 [PubMed - in process]
Authors: Iyengar SS, Bansal M, Sawhney J, Wander G, Narasingan SN, Chandra KS, D P, Nair T, Krishnakumar B, Deshpande N, Bardoloi N, Shetty S, Desai N, Pancholia AK, Swamy A Abstract The burden of atherosclerotic cardiovascular (CV) disease is alarmingly high and increasing in our country. Dyslipidemia is one of the major modifiable risk factors, and INTERHEART study showed that dyslipidemia had the highest population attributable risk for myocardial infarction. In the management of dyslipidemia, low-density lipoprotein cholesterol (LDL-C) is the primary therapeutic target. In addition to therapeutic lifestyle chan...
More News: Atorvastatin Calcium | Blogging | Cardiology | Cardiovascular | Cholesterol | Diets | Egg Yolk | Heart | Hospitals | Insulin | Lipitor | Liver | Men | Nutrition | Primary Care | Saturated Fat | Statin Therapy | Statistics | Sugar | Urology & Nephrology | Vitamin D | Vitamins | Wheat | Zivast